Core Points - The company has announced the implementation of the 2024 annual profit distribution plan, which was approved at the shareholders' meeting on May 30, 2025 [1] - The profit distribution plan includes a cash dividend of 1.70 RMB per 10 shares (before tax) to all shareholders, based on the total share capital minus the shares in the company's repurchase account [1][2] - The total share capital as of April 24, 2025, is 419,982,466 shares, with 2,333,442 shares in the repurchase account, resulting in 417,649,024 shares eligible for the dividend distribution [1][2] Profit Distribution Plan - The cash dividend distribution will be differentiated based on the type of shares held, with specific tax treatments for different categories of investors [2] - The cash dividend for investors holding shares for less than one month will incur a tax of 0.34 RMB per 10 shares, while those holding for more than one month but less than one year will incur a tax of 0.17 RMB per 10 shares [2] - The record date for the dividend distribution is set for June 20, 2025, and the ex-dividend date is June 23, 2025 [2][3] Dividend Calculation - The actual cash dividend per share, after adjustments, is approximately 0.1690554 RMB per share [3] - The ex-dividend reference price will be calculated based on the previous closing price minus the cash dividend [3] Dividend Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [4] Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodians [4] - The company assumes all legal responsibilities for any discrepancies in the cash dividend distribution due to changes in shareholders' account balances [4] Adjustment of Parameters - The company will adjust the minimum selling price for shares held by certain shareholders in accordance with the profit distribution [6]

| 发行人全称 | 板块 | 审核状态 | 注册地 | 行业分类 | 保荐机构 | | --- | --- | --- | --- | --- | --- | | 上海超硅半导体股份有限 | 科创板 | 已受理 | 下滑 | 计算机、通信和其 | 长江证券承销保 | | 公司 | | | | 他电子设备制造业 | 荐有限公司 | | 深圳市恒运昌真空技术股 | 科创板 | 已受理 | 广东 | 专用设备制造业 | 中信证券股份有 | | 份有限公司 | | | | | 限公司 | | 西百菲乳业股份有限公 | 主板 | 已受理 | 广西 | 食品制造业 | 国融证券股份有 | | lo | | | | | 限公司 | 招股书显示，百菲乳业主要从事乳制品和含乳饮料的研发、生产与销售，产品包括以生水牛乳、生牛乳为主要原料的灭菌乳、调制乳、发酵乳、巴氏杀菌乳 和含乳饮料等。 智通财经APP获悉，6月13日，上交所披露，广西百菲乳业股份有限公司(百菲乳业)、深圳市恒运昌真空技术股份有限公司(恒运昌)、上海超硅半导体股份有 限公司(上海超硅)上交所IPO申请已获受理。 上海超硅主要从事全球半导体市场需求最大的300 m ...

Mergers and Acquisitions - Bozhong Precision plans to acquire 70% stake in Shanghai Wodian for 420 million yuan, aiming to enter the automotive intelligent equipment market and establish a diversified business model of "3C + new energy + automotive" [1] Shareholding Changes - Hengrui Medicine's senior vice president plans to reduce holdings by up to 47,670 shares, representing 0.007% of the total share capital due to personal financial needs [2] - Guomao Co., Ltd.'s actual controller plans to reduce holdings by up to 19,772,600 shares, accounting for 3% of the total share capital, with a minimum selling price not lower than the IPO price [3] - Baoli International's shareholder plans to reduce holdings by up to 27,468,000 shares, representing 3% of the total share capital after excluding repurchased shares, due to personal financial needs [4] Risk Matters - Yong'an Pharmaceutical warns of high speculation risk as its stock price has surged significantly, deviating from the market trend, although there are no major changes in fundamentals [5] - ST Kevin alerts investors about rational investment and risk awareness due to a cumulative price deviation of 12.32% over three trading days, confirming no violations of fair information disclosure [6] - Annie Co. states that there are no undisclosed significant matters, despite a cumulative price deviation exceeding 20% over two trading days, and confirms stable operational conditions [7]

启明创投收购天迈科技实控权的交易结构日前出炉，其复杂的"双GP+关联方管理人委托管理"模式，迅 速成为机构人士热议焦点。不少受访者将其视为地方国资入主上市公司新范式。 经历了纾困式并购、证券化率提升式并购等模式之后，地方国资"朋友圈式"入主A股的并购案例增多， 尤其是产业方成为国资牵手的重要伙伴，无论是实干者还是GP，背后都体现出地方国资对专业性和收 益性的新权衡。在模式演变中，一些地方国资之间演绎新的竞合节奏，相较于股权增值，其诉求也更加 侧重于做招商、做产业、培养新质生产力。 多数受访者认为，这种"朋友圈式"并购未来会成为一种主流选择。但新模式具有双面性，如何应对掌控 力的变相弱化、整合管理等多维风险，此类运作也面临着一些挑战。 | 近期 | | "国资+产业"收购控股权部分案例一览 | | | --- | --- | --- | --- | | 上市公司 | 所属行业 | 并购方 | 并购方类型 | | 跃岭股份 | 交通运输设备 | 杰思金材 | 南宁国资+产业 | | 汇纳科技 | 软件服务 | 上海金石一号 | 上海国资+产业 | | 超达装备 | 专用设备制造 | 南京友旭 | 山东国资+青岛国 ...

重庆基地投产+收购珠海九源，内生+外延共促高成长 证券研究报告 | 公司点评 | 专用设备 ——日联科技点评报告 投资要点 q 事件 1：公司通过收购与增资，将持有珠海九源 55%股权 公司 2025-06-14 日公告，拟使用自有资金 6075 万元收购珠海九源 45%股份，并 对其增资 3000 万元。交易完成后，公司、屈世磊、珠海长乔中益投资合伙企业 将分别持有珠海九源 55%、41.63%、3.37%股份，珠海九源将成为公司控股子公 司，纳入合并报表。 q 珠海九源布局锂电池电性能检测、储能变流器、及电网模拟系统等领域 珠海九源是行业具有核心自主知识产权的新能源电能变换与智能检测设备供应 商，长期专注于锂电池电性能检测、储能变流器及电网模拟系统技术的研发与产 业化，已构建起较为完整的检测设备体系。 业绩承诺：2023、2024 年珠海九源的营业收入分别为 3048、3992 万元，主营业 务毛利率均超过 60%。珠海九源承诺 2025 年 7-12 月、2026 年、2027 年、2028 年实现的净利润分别不低于 500 万元、2,000 万元、2,250 万元、2,500 万元。 q 事件 2：2 ...

Core Viewpoint - Dongfulong Life Science Technology Co., Ltd. has applied for a patent for a single-stage and multi-stage mixer for microfluidic mixing, indicating its focus on innovation in pharmaceutical engineering technology [1] Company Overview - Dongfulong Life Science Technology Co., Ltd. was established in 2015 in Shanghai, primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 100 million RMB [2] - Dongfulong Technology Group Co., Ltd. was founded in 1993 in Shanghai, focusing on specialized equipment manufacturing, with a registered capital of approximately 765.83 million RMB [2] Patent Details - The patent application, published as CN120132922A, was filed on December 2023 and pertains to a microfluidic mixer designed to enhance the mixing effect of two-phase liquids and improve the quality of nanoparticle formation [1] - The mixer includes a diversion section, a convergence section, and at least one liquid level conversion section, which allows for the alteration of the boundary order of liquids to facilitate better mixing [1]

（文章来源：证券时报网） 信宇人6月13日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 瑞银证券有限责任公司上海浦东新区花园石桥路第二证券营业部 | 2350.10 | | 国泰海通证券股份有限公司总部 | 2192.39 | | 中信证券股份有限公司上海溧阳路证券营业部 | 1311.36 | | 华泰证券股份有限公司上海黄浦区黄陂南路证券营业部 | 883.30 | | 中信证券股份有限公司杭州延安路证券营业部 | 706.13 | | 卖出营业部名称 | 卖出金额(万元) | | 国泰海通证券股份有限公司孝感北京路证券营业部 | 1515.00 | | 国泰海通证券股份有限公司总部 | 1482.74 | | 中信证券股份有限公司上海分公司 | 778.18 | | 中国银河证券股份有限公司深圳深南大道证券营业部 | 718.38 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 597.88 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 6月13日信宇人（688573）收盘价24.44元，收盘上涨7.19%，全天换手率3 ...

Group 1 - The company plans to purchase land use rights and invest in the construction of a new precision temperature control energy-saving equipment R&D center and production base, with a total investment of no less than RMB 100 million [1][2] - The company successfully won the bid for a state-owned construction land use right in Longhua District for RMB 24 million, signing a confirmation letter with Shenzhen Trading Group [2] - Acquiring the land use rights is expected to enhance the company's overall image, improve management efficiency, and lay a foundation for long-term stable development [2] Group 2 - The company will proceed with the payment of the land transfer fee and sign the relevant land use rights transfer contract following the confirmation of the bid [2] - The company commits to timely fulfill information disclosure obligations in accordance with legal regulations and normative documents [2]

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting, focusing on governance, financial performance, and strategic initiatives for growth in the pharmaceutical automation sector. Group 1: Meeting Procedures and Governance - The meeting will take place on June 25, 2025, at 14:00 in Shanghai, combining on-site and online voting methods [6][12]. - Attendees must register and present identification to confirm their eligibility to participate [2][3]. - The meeting will include a series of agenda items, including the presentation of reports and voting on various proposals [6][7]. Group 2: Financial Performance - The company reported a net profit of 32,520,676.27 yuan for the year, a decrease of 45.80% compared to the previous year [11][24]. - The total assets of the company reached 146,601.12 million yuan, reflecting growth due to market expansion efforts [24]. - The company has decided not to distribute cash dividends for 2024, with retained earnings of 233,162,211.41 yuan to be reinvested for future growth [10][11]. Group 3: Industry Context and Company Strategy - The pharmaceutical automation industry is experiencing rapid growth driven by technological advancements and increasing healthcare demands [12][13]. - The company is positioned as a provider of comprehensive solutions in the pharmaceutical automation sector, focusing on product design, development, and after-sales service [13][14]. - Strategic initiatives include expanding into international markets, enhancing partnerships with leading retail pharmacies, and developing smart pharmacy solutions [14][25]. Group 4: Future Plans and Innovations - The company aims to enhance its R&D capabilities and expand its market presence, particularly in overseas markets [30][31]. - Plans include leveraging AI technology to improve healthcare services and developing innovative products tailored to market needs [31]. - The company is committed to maintaining strong investor relations and ensuring transparent communication regarding its strategic direction and financial performance [29][31].

调整 2022 年股票期权与限制性股票激励计划 山东国曜琴岛（青岛）律师事务所 关于软控股份有限公司 股票期权行权价格相关事宜的 法律意见书 致：软控股份有限公司 山东国曜琴岛（青岛）律师事务所（以下简称"本所"）接受软控股份有限 公司（以下简称"软控股份"或"公司"）委托，根据双方签署的《专项法律顾 问聘应协议》，担任公司实施 2022 年股票期权与限制性股票激励计划（以下简称 "2022 年激励计划"）事宜之特聘专项法律顾问，根据公司 2022 年激励计划相 关规定，就公司调整 2022 年股票期权与限制性股票激励计划股票期权行权价格 相关事宜（以下简称"本次股票期权行权价格调整"）相关事宜出具本法律意见 书。 为出具本法律意见书，本所律师作如下声明： （一）本所律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办 法》 （四）对本法律意见书至关重要而又无法获得独立证据支持的事实，本所律 师依赖有关行政机关、司法机关、公司或其他有关单位出具的证明文件和说明发 表法律意见，该等文件或说明被视为真实、准确的。 （五）本所 ...